Roth Capital Predicts Electromed FY2025 Earnings

Electromed, Inc. (NYSE:ELMD - Free Report) - Stock analysts at Roth Capital issued their FY2025 earnings estimates for Electromed in a research note issued to investors on Monday, July 21st. Roth Capital analyst K. Bauser forecasts that the company will post earnings of $0.81 per share for the year. Roth Capital currently has a "Strong-Buy" rating on the stock. Roth Capital also issued estimates for Electromed's Q4 2025 earnings at $0.22 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.26 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.15 EPS.

A number of other brokerages have also commented on ELMD. Wall Street Zen lowered Electromed from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley raised shares of Electromed to a "strong-buy" rating in a research report on Thursday, May 15th.

Electromed Stock Performance

ELMD traded up $0.18 during trading hours on Thursday, reaching $18.82. The company's stock had a trading volume of 30,244 shares, compared to its average volume of 87,323. The company's 50-day moving average is $20.22 and its 200-day moving average is $24.50. Electromed has a 52 week low of $13.74 and a 52 week high of $35.56. The firm has a market cap of $157.82 million, a PE ratio of 25.09 and a beta of 0.41.

Institutional Investors Weigh In On Electromed

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new position in shares of Electromed in the 4th quarter worth $37,000. State of Wyoming bought a new position in shares of Electromed in the first quarter valued at $48,000. Quantbot Technologies LP acquired a new position in shares of Electromed during the fourth quarter valued at about $99,000. Bank of America Corp DE increased its position in shares of Electromed by 179.2% during the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company's stock worth $118,000 after acquiring an additional 2,570 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Electromed in the 4th quarter worth about $119,000. Institutional investors and hedge funds own 40.82% of the company's stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.